Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisGordon R. Bernard, Charles J. Fisher, Jean‐Louis Vincent et al.|New England Journal of Medicine|2001Cited by 6.1k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of DeathEdward Abraham, William L. Macias, Pierre‐François Laterre et al.|New England Journal of Medicine|2005Cited by 890
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Pierre‐François Laterre et al.|JAMA|2013Cited by 797
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shockFabio Silvio Taccone, Frédérique Jacobs, Pierre‐François Laterre et al.|Critical Care|2010Cited by 372
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisE. Wesley Ely, Gordon R. Bernard, Pierre‐François Laterre et al.|Critical Care Medicine|2003Cited by 283